Genetic variants identified from GWAS for predisposition to type 2 diabetes predict sulfonylurea drug response

N. M. Phani, M. Vohra, P. Adhikari, S. K. Nagri, U. Shashikiran, S. C. D’Souza, P. R.R. Kalluri, K. Satyamoorthy, P. S. Rai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Several SNPs were identified through GWAS for their association with type 2 diabetes which has implications to pancreatic β-cell physiology. Objective: We aimed to study the role of risk alleles of TCF7L2, KCNJ11, CDKN2A, CDKAL1, IGF2BP2, SLC30A8 and KCNQ1 along with pharmacokinetic variants in response to sulfonylureas. Method: We performed a prospective study on 209 newly diagnosed subjects; treatment naive T2D subjects were recruited. Individuals were started with glibenclamide monotherapy and followed-up for 12 weeks. Genotyping was done, using PCR-RFLP and TETRA-ARMS PCR and confirmed by DNA sequencing. Results: In univariate regression analysis, KCNJ11 (rs5219) was only the predictor for glibenclamide treatment failure. Conclusion: The present data suggests a possible role of KCNJ11 gene in altered response to glibenclamide.

Original languageEnglish
Pages (from-to)580-586
Number of pages7
JournalCurrent Molecular Medicine
Volume17
Issue number8
DOIs
Publication statusPublished - 01-09-2017

Fingerprint

Glyburide
Genome-Wide Association Study
Medical problems
Type 2 Diabetes Mellitus
Pharmaceutical Preparations
Cell Physiological Phenomena
Polymerase Chain Reaction
Pharmacokinetics
Physiology
Treatment Failure
DNA Sequence Analysis
Regression analysis
Restriction Fragment Length Polymorphisms
Single Nucleotide Polymorphism
Genes
Alleles
Regression Analysis
Prospective Studies
DNA

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology

Cite this

Phani, N. M. ; Vohra, M. ; Adhikari, P. ; Nagri, S. K. ; Shashikiran, U. ; D’Souza, S. C. ; Kalluri, P. R.R. ; Satyamoorthy, K. ; Rai, P. S. / Genetic variants identified from GWAS for predisposition to type 2 diabetes predict sulfonylurea drug response. In: Current Molecular Medicine. 2017 ; Vol. 17, No. 8. pp. 580-586.
@article{5f435de621be4b31a6b0c69d63782206,
title = "Genetic variants identified from GWAS for predisposition to type 2 diabetes predict sulfonylurea drug response",
abstract = "Background: Several SNPs were identified through GWAS for their association with type 2 diabetes which has implications to pancreatic β-cell physiology. Objective: We aimed to study the role of risk alleles of TCF7L2, KCNJ11, CDKN2A, CDKAL1, IGF2BP2, SLC30A8 and KCNQ1 along with pharmacokinetic variants in response to sulfonylureas. Method: We performed a prospective study on 209 newly diagnosed subjects; treatment naive T2D subjects were recruited. Individuals were started with glibenclamide monotherapy and followed-up for 12 weeks. Genotyping was done, using PCR-RFLP and TETRA-ARMS PCR and confirmed by DNA sequencing. Results: In univariate regression analysis, KCNJ11 (rs5219) was only the predictor for glibenclamide treatment failure. Conclusion: The present data suggests a possible role of KCNJ11 gene in altered response to glibenclamide.",
author = "Phani, {N. M.} and M. Vohra and P. Adhikari and Nagri, {S. K.} and U. Shashikiran and D’Souza, {S. C.} and Kalluri, {P. R.R.} and K. Satyamoorthy and Rai, {P. S.}",
year = "2017",
month = "9",
day = "1",
doi = "10.2174/1566524018666180222122653",
language = "English",
volume = "17",
pages = "580--586",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

Genetic variants identified from GWAS for predisposition to type 2 diabetes predict sulfonylurea drug response. / Phani, N. M.; Vohra, M.; Adhikari, P.; Nagri, S. K.; Shashikiran, U.; D’Souza, S. C.; Kalluri, P. R.R.; Satyamoorthy, K.; Rai, P. S.

In: Current Molecular Medicine, Vol. 17, No. 8, 01.09.2017, p. 580-586.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Genetic variants identified from GWAS for predisposition to type 2 diabetes predict sulfonylurea drug response

AU - Phani, N. M.

AU - Vohra, M.

AU - Adhikari, P.

AU - Nagri, S. K.

AU - Shashikiran, U.

AU - D’Souza, S. C.

AU - Kalluri, P. R.R.

AU - Satyamoorthy, K.

AU - Rai, P. S.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background: Several SNPs were identified through GWAS for their association with type 2 diabetes which has implications to pancreatic β-cell physiology. Objective: We aimed to study the role of risk alleles of TCF7L2, KCNJ11, CDKN2A, CDKAL1, IGF2BP2, SLC30A8 and KCNQ1 along with pharmacokinetic variants in response to sulfonylureas. Method: We performed a prospective study on 209 newly diagnosed subjects; treatment naive T2D subjects were recruited. Individuals were started with glibenclamide monotherapy and followed-up for 12 weeks. Genotyping was done, using PCR-RFLP and TETRA-ARMS PCR and confirmed by DNA sequencing. Results: In univariate regression analysis, KCNJ11 (rs5219) was only the predictor for glibenclamide treatment failure. Conclusion: The present data suggests a possible role of KCNJ11 gene in altered response to glibenclamide.

AB - Background: Several SNPs were identified through GWAS for their association with type 2 diabetes which has implications to pancreatic β-cell physiology. Objective: We aimed to study the role of risk alleles of TCF7L2, KCNJ11, CDKN2A, CDKAL1, IGF2BP2, SLC30A8 and KCNQ1 along with pharmacokinetic variants in response to sulfonylureas. Method: We performed a prospective study on 209 newly diagnosed subjects; treatment naive T2D subjects were recruited. Individuals were started with glibenclamide monotherapy and followed-up for 12 weeks. Genotyping was done, using PCR-RFLP and TETRA-ARMS PCR and confirmed by DNA sequencing. Results: In univariate regression analysis, KCNJ11 (rs5219) was only the predictor for glibenclamide treatment failure. Conclusion: The present data suggests a possible role of KCNJ11 gene in altered response to glibenclamide.

UR - http://www.scopus.com/inward/record.url?scp=85045896065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045896065&partnerID=8YFLogxK

U2 - 10.2174/1566524018666180222122653

DO - 10.2174/1566524018666180222122653

M3 - Article

VL - 17

SP - 580

EP - 586

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 8

ER -